Portfolio news 2012 Synairgen plc – Preliminary statement of results for the six months ended 31 December 2011 01 Feb 2012

Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence of the lungs, today announces its audited results for the six months ended 31 December 2011 following the change of year-end to that date.

Operational highlights Significant progress on core development programmes:

• Phase II trial of inhaled interferon beta ('IFN-beta') in asthma on schedule: last subjects were dosed in December 2011, with results anticipated in March 2012
• Positive results from pre-clinical study completed in November 2011 showing that aerosolised IFN-beta reduced virus-induced pneumonia, suggesting that inhaled IFN-beta may have potential in two further areas:
  • as a broad spectrum antiviral for use in patients admitted to hospital with suspected viral lung infections; and
  • as a post-exposure prophylactic defence against a lethal virus threat to the lungs
• Business development activity for out-licensing of IFN-beta programme being coordinated to coincide with the availability of key clinical trial data 

Financial highlights

• Research and development expenditure for the period: ?1.8 million (year ended 30 June 2011: ?2.9 million)
• Post-tax loss for the period: ?2.0 million (year ended 30 June 2011: ?3.2 million)
• Cash at 31 December 2011: ?3.4 million (30 June 2011: ?4.9 million)

Commenting on the results, Simon Shaw, Chairman of Synairgen, said: "Positive data from the Phase II asthma trial in March 2012 will be a pivotal requirement for us to pursue the further development of inhaled IFN-beta with a licensing partner. such a partnership would be a significant commercial milestone for the Company and we have an ongoing dialogue with several potential development and commercialisation partners."

For further information, please contact:

Synairgen plc Tel: + 44 (0) 23 8051 2800 Richard Marsden, Chief Executive Officer John Ward, Finance Director FinnCap    Tel: + 44 (0) 20 7220 0500 Geoff Nash, Christopher Raggett (Corporate Finance) Stephen Norcross, Simon Starr (Corporate Broking) Newgate Threadneedle  Tel: + 44 (0) 20 7653 9850 Graham Herring Josh Royston

Following the change of year-end, this report covers the six month period to December 2011, during which time the Company has made significant progress with its Phase II study in asthma and its pre-clinical study of viral pneumonia.

in December 2011 Synairgen completed recruitment for its Phase II proof of concept trial of inhaled interferon beta ('IFN-beta') for the prevention of virus-induced asthma exacerbations (acute and prolonged worsening of asthma symptoms). during January and February 2012, the data will be audited and entered into the database. The results are expected in March 2012. 

We announced in November 2011 that, independent of the asthma development programme, the Company had generated strongpre-clinical data, which opens up the potential for two additional indications related to viral infection in the overall population. these are: 1.   Hospitalised patients with a suspected severe viral lung infection; and 2.   Post-exposure prophylaxis for: a.   Highly pathogenic viruses (for example SARS-like viruses) b.   Common respiratory viruses (for example swine flu) in vulnerable populations

these are attractive potential markets, for which there is today little or no effective therapy. Indeed the area of defence against highly pathogenic viruses has become a focus for a number of governments around the world, which are prepared to commit resource to appropriate programmes. We will be investigating this area during 2012.

Asthma and COPD

Phase II clinical trial – Proof of concept in asthma Common respiratory viruses are the major cause of asthma exacerbations. many different viruses, including RSV, parainfluenza virus, coronavirus, over 200 different types of rhinovirus, and many others, are loosely termed 'common cold' or 'flu' viruses.  Influenza infections tend to be more severe and yet not all suspected influenza infections turn out to be influenza at all; many of the suspected influenza infections will be caused by one of the common cold viruses, and vice versa.

in asthmatic patients, and those with other respiratory diseases such as COPD (chronic obstructive pulmonary disease) or cystic fibrosis, the lungs are unable to defend themselves adequately against these common viruses and an exacerbation can ensue. The poor defence appears to be due to compromised IFN-beta-driven immunity. This can be corrected by introducing a small amount of IFN-beta to help cells defend themselves against viruses. This has been demonstrated in Synairgen's in vitro models, using cells from volunteers with asthma (Synairgen's Biobank). it is very important to note that these vulnerable patients do not become severely ill on account of cold symptoms such as a really bad sore throat or very blocked nose. these patients become ill because of the viral infection in their lungs and the way this interacts with their pre-existing lung disease. Synairgen is developing inhaled IFN-beta for delivery directly to the lungs in the form of an aerosol and is not trying to modulate the incidence or severity of symptoms in the nose and throat.

many therapeutic approaches to tackling viral respiratory infections have failed due to the great diversity and adaptability of these very contagious viruses. Tamiflu? and Relenza? are successful examples of the 'one drug one bug' approach, the bug being influenza. however influenza only accounts for approximately 5 – 10% of all respiratory infections and there remains a concern about progressive resistance; Synairgen's inhaled IFN-beta has the advantage of boosting the body's powerful 'virus agnostic' defences in the lung. it has demonstrated activity against all of the common respiratory viruses and some highly pathogenic viruses such as H5N1 'Bird Flu' and the coronavirus SARS. thus Synairgen's inhaled IFN-beta is increasingly proving itself as an inhaled broad spectrum antiviral defence. Furthermore it is considered that resistance to the activity of IFN-beta is highly unlikely to emerge. Synairgen has been fortunate in that the development of inhaled IFN-beta is a re-profiling exercise.  IFN-beta has been administered by injection to thousands of patients with multiple sclerosis over the years, since its first approval in 1993. This significantly de-risks the inhaled programme as any drug which passes through the lungs to the blood system is unlikely to cause any unexpected adverse events. Furthermore, through its exclusive supply and licence arrangement with the Rentschler Group (a manufacturer of IFN-beta), Synairgen has access to a pH neutral formulation suitable for inhalation.

in the Phase I safety and pharmacodynamic clinical trial, conducted in 2008/09, inhaled IFN-beta was well tolerated in moderate asthmatics. there was also convincing biomarker evidence that even in the absence of a virus inhaled IFN-beta 'switched on' the antiviral defences. This provided the Company with 'proof of mechanism', i.e. that the drug could switch on antiviral defences in the lungs of patients with an IFN-beta deficiency.

The Phase II study reporting results in March 2012 will hopefully confirm that there is benefit in boosting/restoring the IFN-beta-driven antiviral defences in asthmatics. in this blinded clinical trial approximately 150 exacerbation-prone asthmatics have been treated with inhaled IFN-beta or placebo at the onset of cold or flu symptoms. The objective is to boost the lungs' immunity so that, as the virus infection builds in the nose and throat, the lungs are able to defend themselves adequately. The primary endpoint is the sACQ (shortened Asthma Control Questionnaire), which is a measure of asthma symptoms. there are a number of secondary endpoints which may also be very informative for signalling the future development strategy for the drug. these are the AI (the Asthma Index – an alternative measure of asthma symptoms), lung function, virus load, markers of pulmonary inflammation and drug safety.

Phase II clinical trial – Proof of concept in COPD Synairgen has developed a Phase II clinical trial protocol for the COPD population. This study has been approved by the relevant authorities, although it will not commence until a partner has been found through the business development licensing activity.

Business development for the asthma and COPD programmes Synairgen has regularly discussed its IFN-beta programme with major pharmaceutical companies and input from these companies has contributed to the design of the overall development programme. Synairgen has, over the years, generated a package of material necessary for the out-licensing of these programmes for asthma and COPD. This package includes safety data, in vitro efficacy data, granted patents in the US, EU and Japan and biomarker data demonstrating proof of mechanism. The most important pieces of information yet to come will be the analysed outcomes of the Phase II trial in asthma, which are anticipated in March 2012. it is Synairgen's intention to out-license the asthma and COPD programmes on the back of the Phase II results and our continuous interactions with potential business development partners have been designed to expedite this process.

Use of inhaled IFN-beta outside of asthma and COPD

during 2011, Synairgen has completed a series of experiments that have demonstrated reduced lung viral load and reduced cell damage in an advanced viral pneumonia pre-clinical model. The drug was given either prior to infection or post infection. these data open up two new significant applications:

1.   Hospitalised patients with suspected severe viral lung infections Inhaled IFN-beta could be used to treat patients as a therapy (prior to the identification of the virus) upon admission to hospital with breathing difficulties caused by a viral lung infection. The broad spectrum antiviral properties of the drug would be advantageous as it takes some time to identify the causative pathogen. As this is an area of great unmet clinical need, Synairgen believes that, subject to an acceptable safety profile from the Phase II asthma trial, it could be in the interest of a government to support this work either through a grant or an award.

2.   Post-exposure prophylaxis against high pathogenic respiratory viruses The threat posed by emerging respiratory viruses such as SARS or terrorist-manufactured virus threats such as aerosolised Ebola or a variant of H5N1 'bird flu' remains one of significant concern to governments. We understand that governments may be interested in funding the development of a broad spectrum inhaled antiviral that can be stockpiled in sufficient quantities to be issued  to people in the event of exposure to lethal viruses, such as key workers or people placed in quarantine following contact with an infected person (for example on a flight). Synairgen will engage with governmental organisations over the coming months to gauge interest and map out a potential development programme.

• against common respiratory viruses in vulnerable populations

Vulnerable patients, for example transplant patients, pregnant women, the elderly, and the very young, can suffer lung complications due to common viruses migrating from the nose and throat to the lungs. Inhaled IFN-beta could be given to these patients as and when they believe they have been exposed to a viral infection. such exposure could be from a work colleague or somebody they live with. Synairgen will consider the future development of inhaled IFN-beta for this indication following the results of the Phase II asthma trial.

Change of Accounting Reference Date The Group has brought forward its financial year-end from 30 June to 31 December for administrative reasons to expedite the production of its annual report and accounts. As a result the audited financial statements cover the six months ended 31 December 2011 with comparative financial information being given for the year ended 30 June 2011.

Statement of Comprehensive Income The loss from operations for the six months ended 31 December 2011 was ?2.24 million (year ended 30 June 2011: ?3.70 million). Research and development expenditure for the period amounted to ?1.82 million (year ended 30 June 2011: ?2.91 million). The main areas of expenditure have been on the asthma Phase II study (SG005) and the pre-clinical study in viral pneumonia. The last subject was recruited into SG005 in December 2011 and the results are anticipated in March 2012. The significant majority of costs on the pre-clinical study were also incurred prior to 31 December 2011 and therefore expenditure on both these projects will reduce significantly during the first half of 2012.

other administrative costs for the period amounted to ?0.42 million (year ended 30 June 2011: ?0.90 million). The research and development tax credit for the period was ?0.25 million (year ended 30 June 2011: ?0.43 million). The loss after tax for the period was ?1.97 million (year ended 30 June 2011: ?3.23 million) and the loss per share was 2.83p (year ended 30 June 2011: loss of 5.37p).

Statement of Financial Position and cash flows At 31 December 2011, net assets amounted to ?3.12 million (30 June 2011: ?4.99 million), including net funds of ?3.35 million (30 June 2011: ?4.89 million). The principal elements of the ?1.54 million decrease over the six months ended 31 December 2011 (year ended 30 June 2011: ?0.12 million decrease) in net funds were:

• Cash used in operations of ?1.93 million (year ended 30 June 2011: ?3.02 million outflow);
• Research and development tax credits received of ?0.40 million (year ended 30 June 2011: ?0.38 million); and

Share issue proceeds (net of costs) ?nil (year ended 30 June 2011: ?2.50 million).

Positive data from the Phase II asthma trial in March 2012 will be a pivotal requirement for us to pursue the further development of inhaled IFN-beta with a licensing partner. such a partnership would be a significant commercial milestone for the Company and we have an ongoing dialogue with several potential development and commercialisation partners.

Independent of an asthma and COPD licensing transaction, we have a programme to investigate the potential development of inhaled IFN-beta as a broad spectrum antiviral for use in patients admitted to hospital with suspected viral lung infections, and also as a post-exposure prophylactic defence against a lethal virus threat to the lungs.

The last-place Twins had just lost their 93rd game of the season Monday afternoon to the Yankees in new York, and Twins President Dave St. Peter was in his Target Field office.

The Twins played without Joe Mauer, who is being paid $23 million this year and is finished for the season because of pneumonia, and Justin Morneau, who is paid $14 million and is done for the season because of concussion symptoms and a minor knee procedure.

Mauer, 28, who is in the first season of a $184 million, eight-year contract, played in just 82 games this season.

Morneau, 30, who is in the fourth season of an $80 million, six-year contract, played in just 69 games.

Both players’ contracts are guaranteed. I asked St. Peter if he has second thoughts about having signed Mauer and Morneau, both of whom have been American League most valuable player, to such immense deals.

“Absolutely not,” St. Peter said. “We obviously are huge believers in Joe Mauer and Justin Morneau, and we still believe to this day that they will continue to be cornerstone players for this franchise as they have been throughout their contracts. This was obviously a very difficult year for both of them, as well as other people throughout the organization.

“Our job is to support them and their efforts to come into spring training as healthy as they possibly can. hopefully, that will happen. and if it does, I like our chances for both of those guys having huge bounce-back years next year.”

St. Peter said there “absolutely” is no unknown ailment that has sidelined Mauer, who in 2009 won his third AL batting title (.365) with 28 home runs while leading the league in on-base percentage (.444) and slugging percentage (.587).

This season, Mauer finished with three homers while batting .287.

“There is no conspiracy theory relative to Joe Mauer’s health,” St. Peter said. “He admittedly has had a very challenging year, and nobody is more frustrated than Joe. It’s pneumonia. it isn’t Lyme disease. it isn’t Lou Gehrig’s disease. it isn’t anything else.

“He has seen some of the best doctors in the world at the Mayo Clinic. I think they’d tell you if it was anything more than that.”

In his first two starts for the Vikings in 2009, Brett Favre completed 14 of 22 passes for 110 yards and one TD, without an interception, against the Browns in Cleveland, then completed 23 of 27 for 155 yards and two TDs with an interception against the Lions in Detroit.

In Donovan McNabb’s first two starts for the Vikings, he completed seven of 15 passes for 39 yards, no TDs and one interception, against the Chargers in San Diego, then completed 18 of 30 for 228 yards and no TDs or interceptions against the Tampa Bay Buccaneers.

A bunch of Jerry Kill’s pals from his days coaching small college Pittsburg State (Kan.) were at TCF Bank Stadium on Saturday to celebrate his first victory as Gophers coach over Miami (Ohio).

Terry Skrypek, Brother Francis Carr, Frank Asenbrenner, Tracy (Schultz) Warner, Emmy (Treacy) Springer and Rick Cover will be inducted into the inaugural Hill-Murray Hall of Fame at the merged school’s 50th anniversary Saturday before the Pioneers’ 1 p.m. football game against South St. Paul. both teams are 3-0. Ex-Vikings QB Brooks Bollinger is in his first year as Hill-Murray coach.

DON’T PRINT THAT

Timberwolves owner Glen Taylor said Tuesday that Rick Adelman was the top choice of basketball president David Kahn when the Wolves began their search for a coach to succeed fired Kurt Rambis.

“Early in the process, David had put down Rick as his first choice,” Taylor said.

Adelman will be officially announced as coach today at Target Center. Taylor, because the choice was primarily that of Kahn, isn’t expected to attend the news conference. He said Kahn deserves the credit.

Adelman’s deal, the Pioneer Press has reported, is for $20 million for four years. The fourth year is an option year for both Adelman and the Wolves.

“Rick wasn’t clear if he was going to coach or not coach, so we went through the whole process and interviewed everybody else,” Taylor said. “We were prepared to go ahead, and then (Kahn) went back and talked to Rick, and Rick said he wanted to come in and interview.”

Taylor said Kahn was patient and waited through the whole process, talked several more times to Adelman and then brought the coach to Mankato for Taylor to meet.

“We spent an evening together and talked,” Taylor said. “After that, Rick told David he was very interested in coming here. David made him an offer, and they worked it out.”

OVERHEARD

Gophers football coach Jerry Kill, on the medication for his seizures: “So they need to get it figured out; that’s my wife’s job, and that’s why I’ve been married 29 years. She’s a heck of a woman. She’s trying to get it figured out, and we’ve got good medical people here, and they’ll eventually get it figured out.”

My friend adopted a 6 month old dog from pet finder, they told her shes good health and passed vet exam, also papers to prove it. after first night home got sick and $1000 later told her she has pneumonia. what to do, and did she get it from where she came from and how long before shows symptoms. Pet finder does ant have a no. to contact them. I am also n the middle of adopting my second dog from them but now I am scared. tank you.

Like it or not, sickness often infects you and your friends. if a handful of people you know have the flu, chances are pretty high that you’ll come down with it too. it was inevitable, then, for the social side of illness tracking to make its way onto the Internet.

The most obvious manifestation of social sickness tracking can be seen with Sickweather, a new startup that mines data from Twitter, Facebook, and user input to show which illnesses are going around in your local area–and in your friend group. the service explains, “just as Doppler radar scans the skies for indicators of bad weather, Sickweather scans social networks for indicators of illness.”

Eventually, Sickweather hopes to track symptom keywords (i.e. “runny nose,” and “cough”), but for now it’s focusing on simpler terms like “pneumonia” and bronchitis.” Illnesses are shown on a map, and in future versions, users will be able to track sicknesses via cell phone (new alert: stay away from Sarah, she’s super germy!).

Social sickness tracking can also be seen with Google’s Dengue Trends, a tracking tool for dengue feveroutbreaks that mines web search results from Brazil, Bolivia, India, Indonesia and Singapore to generate an early-warning system for outbreaks. Users won’t be able to see who exactly is searching for dengue fever symptoms, but they will know when an outbreak is headed their way. Google’s Flu Trends performs a similar purpose–and is probably more useful for people outside of dengue-heavy countries.

We can probably expect to see more initiatives like this in the future. Scientists recently discovered, for example, that weather forecasts can predict cholera outbreaks. so in the future, Google (or a service like HealthMap) could mash up weather predictions with symptom reports in cholera-prone areas for another kind of early warning system.

For now, though, tracking illness outbreaks via sites like Sickweather may be the simplest way to make sure you avoid coming down with a cold–or something worse.

[Image by Flickr user Svenstorm]

Reach Ariel Schwartz via Twitter or email.

Lung cancer is a major killer of men and ladies throughout the country. oxygen pollutants, secondhand smoke, cigarette smoking especially, in addition to other causative factors contribute to the disease.

Most folks believe how the lung cancer is generally usual one of many cigarette smokers as well as it is really true how the great the greater portion of cases are or have been smokers. but there are non-smokers do get lung cancer and smokers who don’t get it.

Signs of lung cancer are generally not apparent in the early stages. nevertheless it is really more effective to uncover lung cancer as possible.

The most usual early symptom of lung cancer is haemoptysis (coughing up blood). Consider this early symptom a warning indication of the cancer, which may pretty properly be curable.

If you obtain that you simply are coughing up blood, you’ll should immediately get in touch with your doctor , in particular in the event you’re 40 many years of age, or older, having a long-term smoking habit.

Some of the main signs include:

* Hacking, prolonged cough* Coughing up blood * Shortness of oxygen * Wheezing * Chest ache * missing hunger * missing weight * Recurring bronchitis or pneumonia

The earlier mentioned signs or symptoms also being the signs or symptoms of many other lung problems, so it is really always advisable to figure out a physician to ascertain the cause

Secondary signs of simple cellular lung cancer include:

* Weakness * Difficulty swallowing * improvements in nails* Hoarse or raspy voice * sizeable fever * inflammation of facial features

It’s true that most signs or symptoms of lung cancer do not show by themselves till the disease is in its sophisticated stages.

However, from the perfect time to time people demonstrate signs early in the disease’s development. it is really essential how the in the beginning notice of signs or symptoms or concern sends you straight to the doctor.

The sooner treatment is begun, the better. A cure is possible if caught early enough and, if not, then a more effective level of quality of life and more of it.

When lung cancer spreads to other elements of the body, organs and bones, known to as ‘metastasizing’, signs and signs or symptoms include:

* Aching and sharp bone ache * improvements in the human brain that demonstrate by themselves through weakness, numbness, dizziness, and seizure * Jaundice (whites of eyes, nails, and skin yellow)* Masses near the skin’s surface* Headaches* Numbness and the decrease of feeling in your extremities

All of these signs and signs or symptoms of lung cancer may pretty properly be caused by other health problems. the only way to know for confident is to search for guidance from your doctor as quickly as possible.

Lung cancer late illness is serious, so families must complete lung cancer late the patient’s nursing home care, giving patients the appropriate for lung cancer patients take care of life, create a good rest environment, the biggest mental support for patients with mental comfort. in addition to traditional Chinese medicine can undertake recuperating cancer. Lung cancer late nursing mainly to control symptoms patients and reduce pain for the target.

Lung cancer late home care of content:

1. Relieve symptoms: fever for lung cancer, one of the main symptoms should instruct client to keep warm, prevent colds, lest produce pneumonia; for irritating cough, can give antitussive agent; Persistent cough, night patient can drink hot water, in order to reduce throat stimulation; if there are coughing up blood shall give hemostatic medicine, a lot of coughing up blood immediately notify the doctor, while allowing patients to a side, head timely removal in oral cavity hemorrhage, and assist doctors to prevent suffocation rescues.

2. Lung cancer patients once appear, typical symptoms, quite part is lung cancer late. Therefore, regular high-risk patients for x-rays and screening for lung cancer, the inchoate discovery, inchoate cure to have the important meaning.

3. Watch the condition change of haemoptysis is more, should be ready in lung cancer patients, prevent suffocate. Rescue articles

4. Understand lung cancer patients’ diets, sleep and psychological state, strengthen the psychological nursing, make patients at a good state of mind and body state in order to raise the therapeutic effect.

5. Psychological care: lung cancer patients will have of late anxiety, fear, sadness, also often appear psychological indifference, loneliness, we want to have a high sympathy and responsibility, for patients to create a warm harmonious culture environment, situated on a single ward, language kind, genuine, encourage patients to speak their psychological feeling, timely, introduced the initiative to convince patients with the improved information. So patients afraid of being cold and period be abandoned, he often felt lonely, especially at night, always feel that death is coming, family care can make patients feel safe, comfortable, warmth. We should take all kinds of measures to alleviate the suffering of patients, and this is to be the basis of mental nursing.

Expert introduction to the stand or fall of nursing, lung cancer late the consolidation of the curative effect of lung cancer has a decisive role. in lung cancer during treatment, reasonable lung cancer care, can greatly improve the body function, make patients with better tolerate treatment. and during the recovery, lung cancer still not neglect nursing, good care can promote lung cancer patients recover.

When I read or hear about any disease or symptoms I freak out because i feel that I am infected by that disease is there any body out there suffering from a similar problem?

That is called hypochondria. that is a symptom that you DO have.

it's a condition (mental illness) called hypochondria. where you think you have an illness and you really dont.

In some cases the individual will say, ' i have pneumonia.' they go to a doctor and they do not have the illness. Then they will force themselves to get the illness, to prove that they have pneumonia.

but relax, go for your yearly checkups (or bi-yearly) and tell them your concerns… but I think it's in your head. remember only a doctor can diagnose an illness.

I used to when I was younger. A few things got me past that.
1. Sick people are not attractive. if you are sick and weak you are not attractive to other people.
2. I worked at a doctor's office and saw people that WERE sick. if you are up running around having a good time you are not sick. Don't waste your time worrying about illness. if you are truly sick you won't be able to get out of bed.
3. Life is short. Live it to the fullest, and enjoy it. Don't waste it looking for something to be wrong.
4. go to the doctor for an annual or semi-annual checkup. if the doctor give you a clean bill of health that is good enough. go enjoy your life.

Lung cancers tend to spread very early, and only 15% are detected in their early stages. The chances of early detection, however, can be improved by seeking medical care at once if any of the following are the early symptoms appear:

– a cough that does not go away
– chest pain
– shortness of breath
– recurrent lung infections, such as bronchitis or pneumonia
– bloody or brown-colored spit or phlegm (sputum)
– persistent hoarseness
– significant weight loss that is not due to dieting or vigorous exercise; fatigue and loss of appetite
– unexplained fever

Although these symptoms may be caused by diseases other than lung cancer, it is important to consult a doctor to rule out the possibility of lung cancer.

If lung cancer has spread to other organs, the patient may have other symptoms such as headaches, bone fractures, pain, bleeding, or blood clots.-

> SOUTHERN INDIANA — A Southeast Indiana farm has reported the state’s first case of bovine tuberculosis in more than 30 years, according to an Indiana State Board of Animal Health press release. The disease was found in a cow that had undergone a routine test during slaughter at a meat processing facility in Michigan. Denise Derrer, State Board of Animal Health public information director, would not release the name of the farm or which county the infected animal came from until an investigation has been completed. she said the cattle herd will be tested — including animals that have been sold to other farms and products received by the farm. “[We will] quarantine any suspect animal from that farm until the testing is complete,” she said. According to the board, bovine tuberculosis is a chronic bacterial disease that affects primarily cattle, but can be transmitted to any warm-blooded animal. The disease is difficult to diagnose in the early stages, but later symptoms may include emaciation, lethargy, weakness, anorexia, low-grade fever and pneumonia with a chronic, moist cough. Lymph node enlargement may also be present. Cattle owners who notice these signs in their livestock should contact their private veterinarian. “The risk to humans is if someone consumes raw milk,” Derrer said. “This wasn’t a dairy [cow] that we found it on.” she added the animal that was diseased was not processed for human consumption. in addition to unpasteurized milk, Derrer warned that any cheese, butter or other product containing unpasteurized milk could put someone at risk of contracting the disease. The health board also is coordinating efforts with the Indiana Department of Natural Resources to determine if the disease is present in free-ranging deer in the area, according to the release. The last time a case of bovine tuberculosis was confirmed in Indiana was in the 1970s and the state has had a bovine tuberculosis-free status since 1984 with the U.S. Department of Agriculture, according to the release. • For more information about bovine tuberculosis and the investigation visit the State Board of Animal Health website at boah.in.gov

Other than croup. Please don't say croup. I don't want it to be croup. But if it is croup, please remind me of other symptoms.

asthma?
pneumonia?

was going to say croup, right after i was going to tell you to go call your pediatrician and don't trust us, clown-nose.

It's Croup. The barking cough is the only symptom. It generally clears out within a couple of days. no need to panic.

croup, there doesn't have to be any other symptoms. I had it for most of my youth.

Sorry, it sounds like croup. I know the second I hear that horrible sound, it's on to the steroids.

My 2 year old had that about 1 month ago. his only symptom was a barking cough and a little bit of a runny nose. they gave him a liquid steroid for 3 days. After the first day, no more cough. I added a link that talks about symptoms/diagnosis/treatment. my MD also suggested a could mist humidifier and push fluids. good luck!

it could be croup sorry or asthma call the doctor and take him in

Upper respiratory infection?

Croup is easy enough to treat, Bella had it recently and she has asthma, not too bad.

If the child has no other symptoms its very likely is croup. us e a humidifier or even a steamy bathroom to ease the child's breathing.

Just watch the child for a day or two and if he doesn't start to improve then see a doctor or if other symptoms occur.

bronchitis?? Could be that nasty c letter word you don't like as well!

here is some information on it!

Signs and Symptoms
Croup is characterized by a loud cough that may sound like the barking of a seal and may be accompanied by fast or difficult breathing and sometimes a grunting noise or wheezing while breathing.

At first, a child may have cold symptoms like a stuffy or runny nose for a few days and may also have fever. as the upper airway (the lining of the windpipe and the voice box) becomes progressively inflamed and swollen, the child may become hoarse, with a harsh, barking cough.

If the upper airway becomes swollen to the point where it is partially blocked off, it becomes even more difficult for a child to breathe. this happens with severe croup. with severe croup, there may be a high-pitched or squeaking noise when breathing in (this is called stridor). a child will tend to breathe very fast, and the stomach or the skin between the ribs may seem to pull in during breathing since he or she is working hard to get air in to the lungs. The child may also appear pale or bluish around the mouth from not getting enough oxygen. these are signs that a child needs immediate medical attention.

Symptoms of croup often worsen at night and when the child is upset or crying. In addition to the effects on the upper airway, the infections that cause croup can result in inflammation further down the airway, including the bronchi (breathing tubes) and the lungs.

I hate to disappoint you but it sounds like croup. The boy I watch last year had that and he had a barking cough.

it most likely is croup. I had it myself as a kid. i would get it maybe once or twice a year. But you just have to deal with it for a while it might suck really bad yes i know trust me!! but he/she will eventually grow out of it. I do not have it any more.

My son has croup right now. He's had that cough on and off for a couple of years. He's been to the ER before to get steroids because it used to scare me. now that I know more about it, I'm not as worried. (although he has no other medical conditions) HONEY really helps. The darker the better. 1tsp every 4-6 hrs. And the hot shower. my son did that this morning when he had a coughing fit and he's sounding a lot better now.

Did you read my post? my kids have the chicken pox right now. Kids getting sick stinks!!

Reactive airway~

Allergies that make the throat tighten. not necessarily asthma tho.
My 13 yr old has had the "croupy" cough on and off for years…. NOT asthmatic. he needs warm drinks, baths, vaporizor and a doctor appt. to establish any other treatment needed.